Skip to main content
Erschienen in: European Radiology 2/2004

01.02.2004 | Experimental

Distribution of Intramyocardially injected extracellular MR contrast medium: effects of concentration and volume

verfasst von: Gabriele A. Krombach, Ronald Baireuther, Charles B. Higgins, Maythem Saeed

Erschienen in: European Radiology | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

The purpose of this study was to assess the potential of intramyocardially injected Gd-DTPA solution as a marker for distribution of intramyocardially delivered therapeutic solutions. The effects of concentration and volume of the extracellular MR contrast medium Gd-DTPA on signal intensity and spatial extent of enhancement was determined after intramyocardial delivery. In anesthetized pigs (n=11), mixtures of Gd-DTPA (0.15, 0.1 and 0.05 mmol/ml) and Evan’s blue tissue dye (3%) were injected into the wall of the left ventricle. In each pig 1 ml of 0.15 mmol/ml, 2 ml of 0.1 ml and 3 ml of 0.05 mmol/ml Gd-DTPA were injected remote from each other. Arterial blood pressure, heart rate and ECG were monitored throughout the procedure. Five minutes after injections were performed, the pigs were killed and the hearts excised. T1-weighted spin-echo MR images were acquired to measure regional signal intensity (SI) and extent of the enhanced regions. The hearts were sliced and mass of blue stained regions was determined and compared with mass of enhanced areas on MRI. Gd-DTPA significantly (p<0.001) increased regional SI compared with remote myocardium in a concentration dependent fashion (109±4% at 0.05 mmol/ml, 202±7% at 0.1, and 327±6% at 0.15) while the mass of enhanced region was 0.6±0.1 g after injection of 1 ml, 1.4±0.2 g after 2 ml and 2.3±0.3 g after 3 ml (p<0.001). Regression and Bland-Altman analysis revealed that there was close correlation and agreement between MRI and histomorphometry (r=0.98, p<0.001). Magnitude and spatial extent of enhancement depend on concentration and volume of injected contrast medium. Intramyocardial injection of extracellular MR contrast media may be useful as a marker for the extent of distribution of intramyocardially delivered therapeutic solutions.
Literatur
1.
Zurück zum Zitat Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF (1994) Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183PubMed Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF (1994) Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183PubMed
2.
Zurück zum Zitat Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800PubMed Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800PubMed
3.
Zurück zum Zitat Symes JF, Losordo DW, Vale PR, Lathi KG, Esakoff DD, Mayskiy M, Ismer JM (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830CrossRefPubMed Symes JF, Losordo DW, Vale PR, Lathi KG, Esakoff DD, Mayskiy M, Ismer JM (1999) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 68:830CrossRefPubMed
4.
Zurück zum Zitat Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch RR, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG (1999) Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468PubMed Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch RR, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso TM, Lesser ML, Isom OW, Crystal RG (1999) Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100:468PubMed
5.
Zurück zum Zitat Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK (1998) Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115:168PubMed Mack CA, Patel SR, Schwarz EA, Zanzonico P, Hahn RT, Ilercil A, Devereux RB, Goldsmith SJ, Christian TF, Sanborn TA, Kovesdi I, Hackett N, Isom OW, Crystal RG, Rosengart TK (1998) Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J Thorac Cardiovasc Surg 115:168PubMed
6.
Zurück zum Zitat Sarkar N, Rück A, Källner G, Y-Hassan S, Blomberg P, Islam KB, Van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C (2001) Effects of intramyocardial injection of phVEGEF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: angiogenic gene therapy. J Intern Med 250:373 Sarkar N, Rück A, Källner G, Y-Hassan S, Blomberg P, Islam KB, Van der Linden J, Lindblom D, Nygren AT, Lind B, Brodin LA, Drvota V, Sylven C (2001) Effects of intramyocardial injection of phVEGEF-A165 as sole therapy in patients with refractory coronary artery disease—12-month follow-up: angiogenic gene therapy. J Intern Med 250:373
7.
Zurück zum Zitat Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robinson WG Jr, Stiber JA, Correa R, Epstein SE, Unger EF (1995) Effect of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 91:145PubMed Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robinson WG Jr, Stiber JA, Correa R, Epstein SE, Unger EF (1995) Effect of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 91:145PubMed
8.
Zurück zum Zitat Giordano FJ, Ping P, McKirnan D, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med 2:534PubMed Giordano FJ, Ping P, McKirnan D, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK (1996) Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nature Med 2:534PubMed
9.
Zurück zum Zitat Henry T, Annex B, Azrin M (1999) Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 100 (Suppl I):I476 Henry T, Annex B, Azrin M (1999) Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 100 (Suppl I):I476
10.
Zurück zum Zitat Simons M (2000) Phase II, multicenter, double-blind, placebo-controlled, dose-finding study for safety, pharmacokinetics, and efficacy of recombinant fibroblast growth factor (rFGF-2) in subjects with coronary artery disease (CAD): FGF-2 Initiating Revascularization Support Trial (FIRST). J Am Coll Cardiol 36:310CrossRefPubMed Simons M (2000) Phase II, multicenter, double-blind, placebo-controlled, dose-finding study for safety, pharmacokinetics, and efficacy of recombinant fibroblast growth factor (rFGF-2) in subjects with coronary artery disease (CAD): FGF-2 Initiating Revascularization Support Trial (FIRST). J Am Coll Cardiol 36:310CrossRefPubMed
11.
Zurück zum Zitat Laham RJ, Rezaee M, Post M, Sellke FW, Braeckman RA, Hung D, Simons M (1999) Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 27:821PubMed Laham RJ, Rezaee M, Post M, Sellke FW, Braeckman RA, Hung D, Simons M (1999) Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos 27:821PubMed
12.
Zurück zum Zitat Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lessions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108PubMed Inoue M, Itoh H, Ueda M, Naruko T, Kojima A, Komatsu R, Doi K, Ogawa Y, Tamura N, Takaya K, Igaki T, Yamashita J, Chun TH, Masatsugu K, Becker AE, Nakao K (1998) Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lessions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98:2108PubMed
13.
Zurück zum Zitat Schumacher B, Pecher P, Specht BU von, Stegmann TH (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 97:645PubMed Schumacher B, Pecher P, Specht BU von, Stegmann TH (1998) Induction of neoangiogenesis in ischemic myocardium by human growth factors. Circulation 97:645PubMed
14.
Zurück zum Zitat Lederman RJ, Guttman MA, Peters DC, Thompson RB, Sorger JM, Dick AJ, Raman VK, McVeigh ER (2002) Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation 105:1282PubMed Lederman RJ, Guttman MA, Peters DC, Thompson RB, Sorger JM, Dick AJ, Raman VK, McVeigh ER (2002) Catheter-based endomyocardial injection with real-time magnetic resonance imaging. Circulation 105:1282PubMed
15.
Zurück zum Zitat Saeed M, Lee M, Martin A, Krombach GA, Weber O, Lee M, Schalla S, Higgins CB (2002) Feasibility of direct transcatheter delivery of therapeutics to the myocardium using dual X-ray-MR imaging. Int Soc Magn Reson Med, 10th Sci Meeting 18–24 May 2002, p 340 Saeed M, Lee M, Martin A, Krombach GA, Weber O, Lee M, Schalla S, Higgins CB (2002) Feasibility of direct transcatheter delivery of therapeutics to the myocardium using dual X-ray-MR imaging. Int Soc Magn Reson Med, 10th Sci Meeting 18–24 May 2002, p 340
16.
Zurück zum Zitat Yang X, Atalar E, Li D, Serfaty JM, Wang D, Kumar A, Cheng L (2001) Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery. Circulation 104:1588PubMed Yang X, Atalar E, Li D, Serfaty JM, Wang D, Kumar A, Cheng L (2001) Magnetic resonance imaging permits in vivo monitoring of catheter-based vascular gene delivery. Circulation 104:1588PubMed
17.
Zurück zum Zitat Krombach GA, Higgins CB, Günther RW, Kuehne T, Saeed M (2002) MR contrast media for cardiovascular imaging. RoFo 174:819CrossRef Krombach GA, Higgins CB, Günther RW, Kuehne T, Saeed M (2002) MR contrast media for cardiovascular imaging. RoFo 174:819CrossRef
18.
Zurück zum Zitat Kuehne T, Saeed M, Reddy G, Akbari H, Gleason K, Turner D, Teitel D, Moore P, Higgins CB (2001) Sequential MR monitoring of pulmonary with endovascular stents placed across the pulmonary valve in growing swine. Circulation 104:2363PubMed Kuehne T, Saeed M, Reddy G, Akbari H, Gleason K, Turner D, Teitel D, Moore P, Higgins CB (2001) Sequential MR monitoring of pulmonary with endovascular stents placed across the pulmonary valve in growing swine. Circulation 104:2363PubMed
19.
Zurück zum Zitat Saeed M, Lund G, Wendland MF, Bremerich J, Weinmann HJ, Higgins CB (2001) Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction using necrosis specific and extracellular nonspecific contrast media. Circulation 103:871PubMed Saeed M, Lund G, Wendland MF, Bremerich J, Weinmann HJ, Higgins CB (2001) Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction using necrosis specific and extracellular nonspecific contrast media. Circulation 103:871PubMed
20.
Zurück zum Zitat Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307PubMed Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307PubMed
21.
Zurück zum Zitat Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM (2001) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 92:19PubMed Lathi KG, Vale PR, Losordo DW, Cespedes RM, Symes JF, Esakof DD, Maysky M, Isner JM (2001) Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth Analg 92:19PubMed
22.
Zurück zum Zitat Saeed M, Higgins CB, Geschwind JF, Wendland MF (2000) T1-relaxation kinetics of extracellular, intracellular and intravascular MR contrast agents in normal and acutely reperfused infarcted myocardium using echoplanar MR imaging. Eur Radiol 10:310PubMed Saeed M, Higgins CB, Geschwind JF, Wendland MF (2000) T1-relaxation kinetics of extracellular, intracellular and intravascular MR contrast agents in normal and acutely reperfused infarcted myocardium using echoplanar MR imaging. Eur Radiol 10:310PubMed
23.
Zurück zum Zitat Geschwind JF, Saeed M, Wendland MF, Higgins CB (1998) Depiction of reperfused myocardial infarction using contrast enhanced spin echo with gradient echo MR imaging: influence of dose of MR contrast media. Invest Radiol 33:386CrossRefPubMed Geschwind JF, Saeed M, Wendland MF, Higgins CB (1998) Depiction of reperfused myocardial infarction using contrast enhanced spin echo with gradient echo MR imaging: influence of dose of MR contrast media. Invest Radiol 33:386CrossRefPubMed
24.
Zurück zum Zitat Lipton MJ, Bogaert J, Boxt LM, Reba RC (2002) Imaging of ischemic heart disease. Eur Radiol 12:1061CrossRefPubMed Lipton MJ, Bogaert J, Boxt LM, Reba RC (2002) Imaging of ischemic heart disease. Eur Radiol 12:1061CrossRefPubMed
25.
Zurück zum Zitat Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52PubMed Sandstede JJ (2003) Assessment of myocardial viability by MR imaging. Eur Radiol 13:52PubMed
26.
Zurück zum Zitat Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, Unger EF(1997) Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36:78 Lazarous DF, Shou M, Stiber JA, Dadhania DM, Thirumurti V, Hodge E, Unger EF(1997) Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 36:78
27.
Zurück zum Zitat Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ (2002) Incomplete retention after direct myocardial injection. Cathet Cardiovasc Intervent 55:392CrossRef Grossman PM, Han Z, Palasis M, Barry JJ, Lederman RJ (2002) Incomplete retention after direct myocardial injection. Cathet Cardiovasc Intervent 55:392CrossRef
28.
Zurück zum Zitat Rezaee M, Yeung AC, Altman P, Lubbe D, Takeshi S, Schwartz RS, Stertzer S, Altman JD (2001) Evaluation of the percutaneous intramyocardial injection for local myocardial treatment. Cathet Cardiovasc Intervent 53:271–276CrossRef Rezaee M, Yeung AC, Altman P, Lubbe D, Takeshi S, Schwartz RS, Stertzer S, Altman JD (2001) Evaluation of the percutaneous intramyocardial injection for local myocardial treatment. Cathet Cardiovasc Intervent 53:271–276CrossRef
Metadaten
Titel
Distribution of Intramyocardially injected extracellular MR contrast medium: effects of concentration and volume
verfasst von
Gabriele A. Krombach
Ronald Baireuther
Charles B. Higgins
Maythem Saeed
Publikationsdatum
01.02.2004
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 2/2004
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-003-2148-5

Weitere Artikel der Ausgabe 2/2004

European Radiology 2/2004 Zur Ausgabe

Interpretation corner

A frontal mass (2004:2a)

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.